Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Inventory (2020 - 2025)

Xeris Biopharma Holdings' Inventory history spans 6 years, with the latest figure at $68.7 million for Q4 2025.

  • For the quarter ending Q4 2025, Inventory rose 42.55% year-over-year to $68.7 million, compared with a TTM value of $68.7 million through Dec 2025, up 42.55%, and an annual FY2025 reading of $68.7 million, up 42.55% over the prior year.
  • Inventory for Q4 2025 was $68.7 million at Xeris Biopharma Holdings, up from $67.5 million in the prior quarter.
  • The five-year high for Inventory was $68.7 million in Q4 2025, with the low at $14.2 million in Q3 2021.
  • Average Inventory over 5 years is $38.2 million, with a median of $38.5 million recorded in 2023.
  • Year-over-year, Inventory surged 116.9% in 2021 and then grew 17.62% in 2024.
  • Tracing XERS's Inventory over 5 years: stood at $18.1 million in 2021, then soared by 36.52% to $24.7 million in 2022, then surged by 57.02% to $38.8 million in 2023, then increased by 24.04% to $48.2 million in 2024, then surged by 42.55% to $68.7 million in 2025.
  • Per Business Quant, the three most recent readings for XERS's Inventory are $68.7 million (Q4 2025), $67.5 million (Q3 2025), and $67.3 million (Q2 2025).